Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist. Melanoma New Zealand Chief executive Andrea Newland says this ...